Programme
Programme – tentative (latest update November 20, 2025)
Wednesday, April 8, 2026
Wellcome reception, Copenhagen City Hall
Thursday, April 9, 2026
Session 1: Molecular brain tumor classification and concepts in tumor biology
Session 2: Microenvironment
Session 3: AI and novel therapeutic approaches
Session 4: Meningiomas
Session 5: Neurosurgery
Congress dinner (Special registration required)
Friday, April 10, 2026
Session 6: Clinical trials – and radiation therapy
Session 7: Symptom management and quality of life
Session 8: Neuroimaging and theranostics
Session 9: Immunotherapy and trial updates
Programme
Wednesday, April 8, 2026
Programme – tentative (Last updated: November 21, 2025)
19:30
Welcome Reception
Copenhagen City Hall
Come and meet your fellow participants at the Welcome Reception at the beautiful Copenhagen City Hall and enjoy the famous City Hall pancakes. Participation is included in the registration fee.
Programme
Thursday, April 9, 2026
Programme – tentative (Last updated: November 5, 2025)
8:30
Welcome
8:40
Session 1
Molecular brain tumor classification and concepts in tumor biology
Felix Sahm – Heidelberg, Germany
Next level diagnostics
Olivera Casar-Borota – Uppsala, Sweden
Towards a molecular classification of PitNETs
Mario Suva – Boston, USA
Single-cell and spatial transcriptomic analysis of human gliomas
David Scheie – Copenhagen, Denmark
How nanopore sequencing has revolutionized CNS tumors diagnostics
Presentation based on selected abstract
10:20
Coffee / Exhibition / Posters
10:35
Session 2
Microenvironment
Leila Akkari – Amsterdam, The Netherlands
Unveiling macrophage diversity in the brain cancer ecosystem: A matter of plasticity and metabolism
Presentation based on selected abstract
Marco Prinz – Freiburg, Germany
The myeloid side of the brain
11:45
Lunch symposium
TBA
12:45
Session 3
AI and novel therapeutic approaches
Dieter Henrik Heiland – Freiburg, Germany
Molecular guided neurosurgery – from exploration to application
Austin Evans – Tampere, Finland
Multifunctional heparin nanoparticles for therapeutic reprogramming of glioblastoma and beyond
Maria Ormhøj – Odense, Denmark
New CAR T-cell approaches to overcome tumor antigen heterogeneity in brain tumors
Presentation based on selected abstract
13:50
Session 4
Meningiomas
Tiit Illimar Mathiesen – Copenhagen, Denmark
Three pitfalls in meningioma management
Anders Korshøj – Aarhus, Denmark
Nationwide population-based trends in incidence, care, and imaging surveillance of meningioma: Results from 8,134 Danish patients (2010-2023)
Mikkel Schou Andersen – Odense, Denmark
Modelling the meningioma – insights from in vivo and in vitro approaches
Presentation based on selected abstract
14:45
Coffee / Exhibition / Posters
Poster session
15:45
Session 5
Neurosurgery
Philipp Karschnia – München, Germany
RESECTography: Mapping the oncological benefit of surgery for personalized glioma resections
Asgeir Jakola – Gothenburg, Sweden
Supramaximal resection in glioblastoma: Current state of the evidence
Jane Skjøth-Rasmussen – Copenhagen, Denmark
Tumor delineation – an update on fluorescent guided surgery in low grade glioma and meningioma using FG001- a uPAR-targeting fluorescent agent
Presentation based on selected abstract
18:00
Congress dinner – (Special registration required)
Programme
Friday, April 10, 2026
Programme – tentative (last updated: January 13, 2026)
8:30
Session 6
Clinical trials – and radiation therapy
Howard Colman – Utah, USA
Eflornithine plus lomustine improves overall survival and progression-free survival compared to lomustine alone in recurrent astrocytoma, IDH-mutant, WHO grade 3: Updated results of the Phase 3 STELLAR trial
Anna Berghoff – Vienna, Austria
Functional precision medicine: patient derived cell based drug screening in glioblastoma
Kirsi Rautajoki – Tampere, Finland
Progression of IDH-mutant astrocytoma’s after therapy
Vincent Fougner – Copenhagen, Denmark
GBM trial design: Lessons learned and new strategies
Petter Brandal – Oslo, Norway
Proton therapy in brain tumors – will we ever know if the promise is fulfilled?
10:15
Coffee / Exhibition / Posters
10:35
Session 7
Symptom management and quality of life
Florien Boele – Leeds, United Kingdom
Quality of life and neurocognitive functioning in brain tumor survivorship
Karin Piil – Copenhagen, Denmark
Understanding the patient needs to build personalized pathways
Anneli Ozanne – Gothenburg, Sweden
Supportive strategies for patients and families along the brain tumor care pathway
Presentation based on selected abstract
11:45
Coffee / Exhibition / Posters
12:00
Session 8
Neuroimaging and theranostics
Atle Bjørnerud – Oslo, Norway
Applications of artificial intelligence in neuro-oncology imaging
Live Eikenes – Trondheim, Norway
68Ga/177Lu-PSMA theranostic in recurrent high-grade glioma
David Bouget – Trondheim, Norway
From pixels to protocols: advancing neurosurgical decision support with AI-based segmentation and reporting
Presentation based on selected abstract
13:00
Lunch / Exhibition / Posters
14:00
Session 9
Immunotherapy and trial updates
Michael Platten – Heidelberg, Germany
Targeting T cells to clonal driver mutations in glioma
Christel Herold-Mende – Heidelberg, Germany
Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes
Anders Korshøj – Aarhus, Denmark
Window-of-opportunity trials in newly diagnosed GBM – challenges and perspectives
Presentation based on selected abstract
15:30